Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

• Status: Completed
• Trial end date: 2019-03-28
• Target enrollment: 0
• Participant gender: All

Summary

To investigate if Riociguat is effective in the treatment of systemic sclerosis

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Riociguat

Criteria

Inclusion Criteria:

• Men or women aged 18 years and older

• Systemic sclerosis, as defined by ACR/EULAR (American College of Rheumatology/European League Against Rheumatism) 2013 criteria

• dcSSc (diffuse cutaneous systemic sclerosis) according to the LeRoy criteria, ie, skin fibrosis proximal to the elbows and knees in addition to acral fibrosis

• Disease duration of ≤ 18 months (defined as time from the first non-Raynaud's phenomenon manifestation)

• ≥ 10 and ≤ 22 mRSS (modified Rodnan skin score) units at the screening visit

• FVC (forced vital capacity) ≥ 45% of predicted at screening

• DLCO (diffusion capacity of the lung for carbon monoxide) ≥ 40% of predicted (hemoglobin-corrected) at screening

• Negative serum pregnancy test in a woman of childbearing potential at the screening visit

• Women of childbearing potential must agree to use adequate contraception when sexually active. "Adequate contraception" is defined as any combination of at least 2 effective methods of birth control, of which at least 1 is a physical barrier (e.g. condom with hormonal contraception like implants or combined oral contraceptives, condom with intrauterine devices). This applies since signing of the informed consent form until 30 (+5) days after the last study drug administration.

Exclusion Criteria:

• Limited cutaneous SSc (systemic sclerosis) at screening

• Major surgery (including joint surgery) within 8 weeks prior to screening

• Hepatic insufficiency classified as Child-Pugh C

• Patients with isolated AST or ALT >3xULN or bilirubin >2xULN can be included in the trial under the condition of additional monitoring during the trial

• Estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73 m^2 (Modification of Diet in Renal Disease formula) or on dialysis at the screening visit. Patients entering the trial with eGFR 15-29 mL/min/1.73 m^2 will be undergo additional monitoring of renal function

• Any prior history of renal crisis

• Sitting SBP (systolic blood pressure) < 95 mmHg at the screening visit

• Sitting heart rate < 50 beats per minute (BPM) at the screening visit

• Left ventricular ejection fraction < 40% prior to screening

• Any form of pulmonary hypertension as determined by right heart catheterization

• Pulmonary disease with FVC < 45% of predicted or DLCO (hemoglobin-corrected) < 40% of predicted at screening

• Active state of hemoptysis or pulmonary hemorrhage, including those events managed by bronchial artery embolization

• Not permitted prior and concomitant medication

• Pregnant or breast feeding women

• Women of childbearing potential not willing to use adequate contraception and not willing to agree to 4-weekly pregnancy testing from Visit 1 (first administration of study drug) onwards until 30 (+5) days after last study drug intake.